Chimeric antigen receptor (CAR) T and natural killer (NK) therapies may become the future of cancer treatment. Dr Jim Ross explains how bioelectronic assays are a non-invasive, label-free approach built for real-time, dynamic assessment of cell therapy potency.
List view / Grid view
The first comprehensive survey of genomics, transcriptomics, global proteomics and phosphoproteomics has revealed insights into paediatric brain tumours.
Research indicates that activation of the RICTOR/mTORC2 pathway advances cancer metastasis and suggests that inhibiting this signalling may make chemotherapy more effective against colon cancer.
Open innovation – a collaboration between academia and the pharmaceutical industry to further leverage drug discovery expertise and assets
Increasing numbers of companies in the pharma industry are consolidating their services and outsourcing to CROs to reduce business costs. AstraZeneca’s Marian Preston, David Murray and Mark Wigglesworth discuss how this can not only drive innovation but also prove successful in identifying lead compounds, as evidenced through recent collaborations.
Researchers in Brazil have identified seven biomarkers that could be used to indicate which glioma patients are likely to experience an aggressive form of the brain cancer.